Patents by Inventor Baiyong Li

Baiyong Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PCSK9 ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20180024131
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Application
    Filed: February 4, 2016
    Publication date: January 25, 2018
    Inventors: Baiyong LI, Zhongmin WANG, Yu XIA, Peng ZHANG, Wuxian REN, Jinan JIAO, Yuanyuan XU, Dongsheng DAI
  • AN ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USES
    Publication number: 20170216433
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Application
    Filed: July 31, 2015
    Publication date: August 3, 2017
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang
  • Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
    Patent number: 6878522
    Abstract: The present invention relates to the discovery that PDG2 is the nautral ligand for orphan receptor CRTH2, which interaction, it will now immediately be recognized, is important in the development of valuable pharmaceuticals. The present invention is therefore related to methods for screening for therapeutic compounds useful in the treatment of PGD2-related disorders such as allergy, asthma and inflammation. Appropriate assay methodology is also disclosed.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: April 12, 2005
    Inventors: Baiyong Li, Kuldeep S. Neote, Ronald P. Gladue, John B. Cheng, Paul H. Bauer, Jiansu Zhang
  • Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2
    Publication number: 20020022218
    Abstract: The present invention relates to the discovery that PDG2 is the nautral ligand for orphan receptor CRTH2, which interaction, it will now immediately be recognized, is important in the development of valuable pharmaceuticals. The present invention is therefore related to methods for screening for therapeutic compounds useful in the treatment of PGD2-related disorders such as allergy, asthma and inflammation. Appropriate assay methodology is also disclosed.
    Type: Application
    Filed: April 11, 2001
    Publication date: February 21, 2002
    Inventors: Baiyong Li, Kuldeep S. Neote, Ronald P. Gladue, John Cheng, Paul H. Bauer, Jiansu Zhang